Stocks · News reference

Guggenheim Maintains Buy on CytomX Therapeutics, Lowers Price Target to $14

Aug 10, 2026, 2:13 PMBenzinga Newsdesk

Guggenheim analyst Michael Schmidt maintains CytomX Therapeutics (NASDAQ:CTMX) with a Buy and lowers the price target from $15 to $14.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

Globenewswire IncSep 1, 2026, 12:00 PMNot Specified
CytomX Therapeutics to Present at Upcoming September Investor Conferences
CytomX Therapeutics announced that management will participate in three major healthcare investor conferences in September 2026, including Wells Fargo, Cantor Global Healthcare, and Morgan Stanley conferences. The company will host fireside chats and one-on-one investor meetings at these events. Live webcasts will be available on CytomX's website.
CTMX
BenzingaAug 27, 2026, 12:01 PMBenzinga Newsdesk
CytomX Therapeutics Says FDA Granted Fast Track Designation To Varseta-M For Relapsed/Refractory Metastatic Colorectal Cancer; Plans Registrational Monotherapy Study Start In 1H 2027
CTMX
BenzingaAug 13, 2026, 3:25 PMBenzinga Newsdesk
JP Morgan Maintains Overweight on CytomX Therapeutics, Lowers Price Target to $11
JP Morgan analyst Anupam Rama maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overweight and lowers the price target from $12 to $11.
CTMX